Published in Am Heart J on March 01, 2010
Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy? | NCT02900170
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ (2012) 1.68
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J (2014) 1.50
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace (2016) 1.40
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33
Update on anti-coagulation in atrial fibrillation. QJM (2011) 1.28
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2012) 1.26
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis (2013) 1.20
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol (2013) 1.20
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. Vasc Health Risk Manag (2011) 0.99
American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation (2011) 0.97
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96
Anticoagulation in atrial fibrillation. BMJ (2014) 0.93
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J (2014) 0.92
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag (2014) 0.91
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
European research priorities for intracerebral haemorrhage. Cerebrovasc Dis (2011) 0.87
Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf (2014) 0.85
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc (2014) 0.85
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc (2015) 0.85
Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation. Yonsei Med J (2012) 0.84
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth (2013) 0.84
Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology (2014) 0.83
Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare. Implement Sci (2011) 0.83
Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. BMC Oral Health (2016) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82
Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J (2011) 0.82
Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2012) 0.80
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm (2014) 0.80
Atrial fibrillation in 2010: advances in treatment and management. Nat Rev Cardiol (2011) 0.79
Prevalence of oral anticoagulation in atrial fibrillation. Clinics (Sao Paulo) (2014) 0.78
New anticoagulants - promising and failed developments. Br J Pharmacol (2012) 0.77
Evaluating the impact of new anticoagulants in the hospital setting. Pharm Pract (Granada) (2011) 0.77
Newer anticoagulants for non-valvular atrial fibrillation. Pharmaceuticals (Basel) (2012) 0.77
Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vasc Health Risk Manag (2015) 0.77
Is dabigatran efficacy enough to prevent stroke in atrial fibrillation patient with high CHADS2 score during peri-procedural catheter radiofrequency ablation? A case report with literature review. Int J Clin Exp Med (2015) 0.77
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev (2013) 0.77
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Assoc (2016) 0.75
The current approach of atrial fibrillation management. Avicenna J Med (2016) 0.75
Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. P T (2011) 0.75
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clin Appl Thromb Hemost (2016) 0.75
Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation, Second Thoughts? Cardiol Res (2012) 0.75
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes (2017) 0.75
New anticoagulants in atrial fibrillation: an update for clinicians. Ther Adv Chronic Dis (2012) 0.75
Rivaroxaban in atrial fibrillation. Vasc Health Risk Manag (2012) 0.75
Gene-drug interaction in stroke. Stroke Res Treat (2011) 0.75
Novel treatments for cardiovascular disease prevention. Cardiovasc Ther (2011) 0.75
The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart J (2015) 0.75
Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. Open Cardiovasc Med J (2016) 0.75
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart (2016) 0.75